Hyris fully embraces the immunology sector to better fight


LONDON, December 15, 2021 (GLOBE NEWSWIRE) – As the COVID-19 pandemic continues to cause concern, with new variants spreading around the world, it is now widely recognized that we need to move beyond a “test and trace“single approach. World leaders and healthcare institutions today aim to achieve high immunity levels among the population, faced with the unprecedented challenge of global vaccination campaign against an emerging virus, for which no vaccine existed until a year ago.

Along with our genetic testing to detect SARS-CoV-2 anywhere and anytime, we knew we needed to put our knowledge to work for vaccination campaigns even further, taking advantage of the versatility of our platform. ‘AI to deliver a new type of immunology test.So tell me Stefano Lo Priore, Founder and CEO of Hyris, a global biotechnology company renowned for its innovations and inclusive approach to genetic analysis. Hyris offers a wide range of solutions to support the fight against COVID-19 around the world. Several health professionals and decision-makers have already used the Hyris systemMT to reliably detect the presence of all major variants of concern.

As a key part of a long-term strategy to fight COVID-19, Hyris continues to support research in immunology, now presenting its new test to detect the body’s T cell immune response to SARS-CoV-2 December 17, 2021, at “A-WISH”, Alicante-Winter Symposium of Immunology in Health. Organized by the Spanish Society of Immunology (SEI) and the University of Alicante (UA), the “A-WISH” Symposium promotes the advancing the study of immunology, infectious diseases and vaccinology as well as life and health sciences. This first edition aims specifically to address strategies for the response to COVID-19 and pandemic preparedness, the development of vaccines against SARS-CoV-2 and the immunological response to infection and different COVID-19 vaccines.

Until now, antibody tests were considered the only tool to measure SARS-CoV-2 immunity,” Explain Isabella Della Noce, Chief Biologist at Hyris,but individuals exposed to the virus or vaccinated do not necessarily develop or maintain antibody positivity. That’s why we need to focus on T cells because they work with antibodies to prevent the spread of pathogens and eliminate cells infected with the virus. An individual who is negative for an antibody test could still be immune, thanks to reactive T cells. Therefore, measuring T cell response is a disruptive new approach to fight SARS-CoV-2. “

The new Hyris T-Cells clinical trial was developed through exclusive agreements between Hyris and renowned scientific health organizations, such as the Singapore Duke-NUS Medical School and the New York Ichan School of Medicine at Mount Sinai, all two renowned worldwide for their publications and studies in the fields of immunology and virology.

“This new test allows rapid assessment of T cell immune responses in recovering COVID-19 patients as well as those vaccinated, also indicating where patients are responding due to vaccination, exposure to the virus, or both. ” precise Lorenzo Colombo, Global Technical Director at Hyris. “And that’s where PCR testing comes in. Not only does the data show that PCR is fully comparable in accuracy and sensitivity with other tests traditionally used to measure the body’s immune response, it is more convenient and faster as a widely used diagnostic technology. a new dimension for vaccine strategies. “

This new test workflow has already been adopted by international projects and research committees, such as VACCELERATE, the European program for the acceleration of phase 2 and 3 COVID-19 vaccine trials and the creation of a pan-European platform for the design and conduct of clinical trials, and the Spanish government project Ene-Covid, the “Estudio Nacional de sero-Epidemiología de la Infección por SARS-CoV-2 en España“.

To support and validate vaccination campaigns around the world, we need much greater access to accurate tests, especially in the area of ​​immunology ”, concludes Lo Priore. “This disruptive approach can also be applied to other areas of immunology, such as oncology or related to even more specific human pathogens. It can also strategically focus on specific patient categories, such as, for example, immunocompromised, transplant or cancer patients. Our immune system really is the perfect “source code” that we know of for how to take care of life. “

The 2021 “A-WISH” Symposium will bring together a group of immunologists, microbiologists, molecular biologists, epidemiologists, virologists and internationally renowned professionals from a wide range of disciplines in the biomedical field to present and discuss the the most recent research results and scientific innovations in immunology. Hyris will participate in the discussion, aimed at accelerating the development of new approaches to disease prevention.

Contact a Hyris expert to find out how to go beyond your current diagnostic capabilities, at [email protected].

Related images

Image 1: Hyris shows off its disruptive T cell test to detect the body’s immune response to SARS-CoV-2.

A doctor holding a tablet showing the HYRIS bAPP â„¢

This content was posted through the press release distribution service at Newswire.com.

  • Hyris presents its disruptive T cell test to detect the body’s immune response to SARS-CoV-2.


About Author

Comments are closed.